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Abstract
Obesity is a serious health problem worldwide associated with an increased risk of life-threatening
diseases such as type 2 diabetes, atherosclerosis, and certain types of cancer. Fundamental for the
development of novel therapeutics for obesity and its associated metabolic syndromes is an
understanding of the regulation of fat cell development. Recent computational and experimental
studies have shown that microRNAs (miRNAs) play a role in metabolic tissue development, lipid
metabolism and glucose homeostasis. In addition, many miRNAs are dysregulated in metabolic
tissues from obese animals and human, which potentially contributes to the pathogenesis of
obesity associated complications. In this review, we will summarize the current state of
understanding of the roles of miRNAs in metabolic tissues under normal development and obese
conditions, and discuss the potential use of miNRAs as therapeutic targets.
Keywords
adipogenesis; adipose tissue; biomarker; diabetes; glucose homeostasis; insulin resistance; lipid
metabolism; liver; microRNAs; obesity; pancreas; therapeutics
1. Introduction
Gene expression in human is precisely controlled in a cell, temporal, and condition specific
manner. Therefore, completely understanding the regulatory mechanisms of gene expression
is important in genomic medicine. One of the major discoveries in the last decade is
microRNAs (miRNAs), which constitute an abundant and evolutionarily conserved class of
post-transcriptional regulators of gene expression1–3. miRNAs are small endogenous
noncoding RNAs that base pair to sites within target mRNAs, triggering either a block in
translation or mRNA degradation or both4, 5. The expression of miRNAs is often tissue-
specific or developmental-specific1, 2. The post-transcriptional programs controlled by
miRNAs affect diverse biological processes, including development, cell differentiation,
apoptosis, immune responses, metabolism and many diseases including various cancers,
cardiovascular disease, viral infection and neurodegenerative diseases6–14. As example,
signature miRNA expression patterns differentiate many types of related cancers better than
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more classical analyses of mRNA profiles or protein markers, and allow better prognosis of
disease progression15.
As outlined in Figure 1, miRNAs are transcribed by polymerase II or polymerase III to
primary transcripts (pri-miRNAs) in the nucleus. Endonuclease Drosha and its cofactor
DGCR8 process pri-miRNA by cutting it at the bottom of its stem loop to ~70-nucleotide
precursors (pre-miRNAs). Upon export to the cytoplasm by exportin 5 and Ran-GTP, Dicer
generates a ~22 nucleotide miRNA duplex. One strand (mature miRNA) is then
preferentially retained in the RNA-induced silencing complex (RISC) and base pairs with
specific sequences in their target mRNAs. Depending on the level of complementarity,
silencing of the transcript can occur via Argonaut-dependent mRNA cleavage or
translational repression or both. The translationally repressed mRNA is either stored in P-
bodies or enters the mRNA decay pathway for destruction16.
miRNA targeting is primarily through seed-matched sites located within favorable predicted
contexts in 3' untranslated regions (UTRs). Both computational and experimental studies
show that each miRNA likely targets ~400 mRNAs and that almost half of the mRNAs in
mammalian cells are targeted by one or more miRNAs3. As a group, miRNAs may directly
regulate expression of over 30% of human and mouse genes and more than 60% of human
protein-coding genes have been under selective pressure to maintain pairing to miRNAs3, 17.
Furthermore, miRNAs are attractive candidates to be involved in complex diseases such as
obesity because the simultaneous coordination of a large number of target genes, potentially
accomplished by a single miRNA, may be key to defining specific pathogenic cell states.
Although miRNA expression profiles and functions have been extensively investigated in
the hematopoietic and neuronal systems18, 19, little is known about the role of miRNAs in
metabolic tissues, particularly adipose tissue10. More recently, several intriguing studies
have uncovered critical roles of miRNAs in the development of metabolic tissues such as
adipose tissue and pancreas. Many miRNAs are also dysregulated in metabolic tissues from
obese animals and humans, and possibly involved in the tissue dysfunction and secondary
complications associated with obesity and diabetes. The purpose of this review is to
summarize the most recent progress in understanding the roles of miRNAs in metabolic
tissues under normal development and obese conditions and to provide a perspective to
future research directions in order to utilize miRNAs as diagnostic markers or therapeutic
targets.
2. miRNAs in metabolic tissues
2.1 Adipose tissue
Adipose tissue is not only a storage depot of triglycerides, but also an endocrine organ and
an important regulator of whole-body energy homeostasis20–22. Adipocyte-specific proteins
induced during differentiation, such as adiponectin, resistin, and leptin regulate many
aspects of lipid and glucose metabolism in adipose tissue, muscle, and liver, and via actions
on the brain that affect food intake23, 24. The development of obesity depends on the
coordinated interplay of adipocyte hypertrophy (increased fat cell size), adipocyte
hyperplasia (increased fat cell number), and angiogenesis25. Both adipocyte hypertrophy and
hyperplasia occur during normal growth phases and the development of obesity. As
discussed below, miRNAs are important regulators of fat cell development and insulin
sensitivity (Table 1). Many miRNAs are differentially expressed in different fat depots and
between normal and obese adipose tissue, likely associated with proper function of adipose
tissue.
Xie et al. Page 2
Expert Opin Ther Targets. Author manuscript; available in PMC 2011 October 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.1.1 miRNA and fat cell development—Adipocytes are derived from multipotent
mesenchymal precursor cells that commit to preadipocytes and then either remain quiescent
or proceed to become differentiated adipocytes26. The differentiation process is tightly
controlled by a combination of multiple transcription factors including peroxisome
proliferator-activated receptor gamma (PPARγ) and extracellular hormones such as
insulin27–29. The first and best characterized model of adipogenesis in vitro is the 3T3-L1
cell line, a substrain of the Swiss 3T3 mouse cell line30. When treated with a combination of
chemicals, post-confluent 3T3-L1 cells undergo clonal expansion, growth arrest and
terminal differentiation. Differentiated adipocytes accumulate lipid droplets and express
genes associated with lipid metabolism (FABP4), glucose homeostasis (GLUT4), and
endocrine functions (adiponectin).
2.1.1.1 miRNA expression: Attempts to catalogue miRNA expression in adipose tissue and
during adipogenesis have been carried out using different profiling platforms. Using a
miRNA cloning strategy, Gu et al cloned 45 known and 2 novel miRNAs from bovine
adipose tissue31. More recently, Liang et al further compared the expression of 345 miRNAs
in 40 normal human tissues by quantitative reverse transcription-polymerase chain reaction
(RT-PCR)32. Unlike neuronal and muscular tissues, their result did not identify any miRNA
expressed exclusively in adipose tissue. One caveat of such tissue profiling studies is that
one could easily get fat contamination when isolating other tissues such as breast.
Interestingly, miRNA profiling in purified mouse primary adipocytes indentified many
adipocyte-enriched miRNAs including miR-103 and miR-143, in comparison to
chondrocytes and osteoblasts, which are also derived from mesenchymal progenitor
cells33–35.
Using Northern blot analyses, Kajimoto et al profiled ~100 miRNAs in mouse preadipocyte
3T3-L1 cells before and after differentiation and showed that 21 miRNAs were either up- or
down-regulated during differentiation36. To provide better sensitivity and coverage, more
recent studies have profiled miRNA expression at different stages of 3T3-L1 differentiation
using a miRNA microarray approach33, 37, 3839, 40. In addition, Xie et al compared the
expression of 12 selected miRNAs by RT-PCR in enriched mouse primary preadipocytes
and adipocytes and suggested that similar changes in miRNA expression occur during in
vitro and in vivo adipogenesis33. There studies offer an overview of miRNA regulation
during fat cell development and identify many candidate miRNAs for further investigation.
Of particular relevance, many miRNAs including let-7, miR-30, 103, 143 and 422b are
upregulated during adipogenesis as suggested by multiple independent studies and
confirmed by either Northern blots or RT-PCR33, 36, 37, 40. Many of these differentially
regulated miRNAs are important regulators of adipogenesis, as discussed below.
2.1.1.2 miRNA function: To infer the global functional role of miRNA in adipose biology,
one can disrupt miRNA processing machinery (Figure 1) by conditional knock-out of Dicer
or DGCR8 in the adipose tissue, similar to studies performed in skin and lung41–43. So far,
such an animal model has not been reported. Nevertheless, in cell culture, knock-down of
Drosha by siRNA two days before induction of differentiation abolished 3T3-L1
adipogenesis38.
The first evidence for participation of individual miRNAs in adipogenesis and lipid
metabolism came from a genetic screen in Drosophila. Xu et al44 found that deletion of
miR-14 results in increased levels of triacylglycerol and diacylglycerol, whereas increases in
miR-14 copy number have the opposite effect. Using a similar method, Teleman et al45
demonstrated that homozygous mutations in the miR-278 gene, which is prominently
expressed in the fat body of flies, causes a smaller fat body and reduced ratio of total body
triglycerides to total protein. This phenotype could be rescued by miR-278 expression.
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Mutant flies also exhibited hyperglycemia in spite of elevated insulin-like peptide levels due
to insulin resistance of the fat body. Thus, miR-278 regulates insulin sensitivity. However,
miR-14 and miR-278 have so far been found only in insects and there are no known
homologues of these miRNAs in mammals.
More compelling evidence for the role of miRNA in adipogenesis has been obtained in
studies of mammalian cells. To screen candidates that have regulatory roles in adipogenesis,
Esau et al37 transfected antisense oligonucleotides targeting 86 human miRNAs into primary
human preadipocytes. Blocking miR-143 effectively inhibited all five adipocyte
differentiation markers by at least 40%, suggesting a pro-adipogenic role of miR-143.
Consistent with this, miR-143 expression increased during mouse adipogenesis in vitro and
in vivo33. In addition, ectopically expressing miR-143 in 3T3-L1 preadipocytes accelerated
fat cell formation33, thus confirming its important role in modulating adipogenesis.
A computational study predicted that the miRNA paralogs miR-103 and miR-107 affect
multiple mRNA targets in pathways that involve cellular acetyl-CoA and lipid
metabolism46. Interestingly, these miRNAs are derived from introns of the pantothenate
kinase gene family members that activate pantothenate for the biosynthesis of coenzyme A.
Experimentally, ectopic expression of miR-103 in 3T3-L1 preadipocytes accelerated
adipogenesis, as measured both by the upregulation of many adipogenesis markers including
PPARγ and FABP4, and by an increase in triglyceride accumulation at an early stage of
adipogenesis33. Based on mRNA profiling and computational predictions, potentially
important mRNA targets for miR-103 includes several anti-adipogenic factors such as
ARNT, FZD1, and RUNX1T1/ETO/MTG8, whose levels are normally downregulated
during adipogenesis33.
Many signaling pathways have an effect on adipogenesis28. For example, insulin and BMP2
promotes adipogenesis while Wnt-family proteins and TGFβ repress adipogenesis.
Therefore, miRNAs activating or inhibiting any of these signaling pathways are likely to
affect adipogenesis. Kennell et al47 identified miR-8 as a negative regulator of Wnt
signaling in Drosophila. They further demonstrated that the miR-200 family, homologues of
Drosophila miR-8 in mammals, promoted adipogenesis. Retroviral expression of miR-200
cluster in mouse ST2 marrow stromal cells increased lipid accumulation and expression of
FABP4 and partially rescued the block of differentiation caused by treatment with
recombinant Wnt3a.
Since clonal expansion is one of the key events taking place in early adipogenesis of 3T3-L1
cells in vitro, any miRNAs affecting this process could have a profound effect on
adipogenesis. Wang et al38 reported that the miR-17-92 cluster, which promotes cell
proliferation in various cancers, is upregulated 2–3 fold during the early clonal expansion
stage of 3T3-L1 adipogenesis. Stable overexpression of these miRNAs moderately
accelerates adipocyte differentiation in vitro after hormonal stimulation. Additionally, this
study provided convincing evidence that Rb2/p130 is a bona fide target of miR-17-92 during
adipogenesis. This is not totally unexpected because previous observations suggested a
p130:p107 switch during the first 24h after hormonal induction of adipogenesis48.
Another miRNA related to clonal expansion is let-7, which is well known to regulate cell
proliferation and differentiation processes in species ranging from C. elegans to human49, 50.
Expression of let-7 slightly decreased from day 0 to day 1 and then increased during
terminal adipogenesis40. Ectopic expression of let-7 by transfecting pre-let-7 oligonucleotide
into 3T3-L1 cells prior to induction of differentiation inhibited clonal expansion as well as
terminal differentiation, in part by targeting HMGA240. Interestingly, mice lacking HMGA2
have marked reductions in adipose tissue51. However, the involvement of the miR-17-92
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cluster and let-7 during in vivo fat cell development awaits further investigation since clonal
expansion is not required for primary preadipocyte differentiation.
Among many downregulated miRNAs during adipogenesis, the miR-27 gene family have
been functionally characterized using 3T3-L1 preadipocytes and OP9 mouse bone marrow
mesenchymal stem cells39. Overexpression of miR-27 by transfecting miR-27 precursors
before adipogenic stimulation specifically inhibited adipocyte formation. Mechanistically,
miR-27 prevents the induction of PPARγ and C/EBPα, the two master transcriptional
regulators of adipogenesis. Interestingly, although PPARγ contains a putative binding site
for miR-27, miR-27 does not repress the level of PPARγ protein in differentiating 3T3-L1
cells if miR-27 was transfected after 2 days after adipogenic stimulation. Therefore, it is
plausible that miR-27 inhibits adipogenesis by targeting an unknown gene that prevents the
transcriptional induction of PPARγ.
It is interesting to note that overexpression of miRNAs that are upregulated during
adipogenesis, namely miR-143, miR-103, miR-17-92, alone without hormonal induction
cannot trigger adipogenesis, suggesting that they are not sufficient to initiate
differentiation33, 38. Similarly, inhibition of endogenous miR-27 using antisense
oligonucleotides is not sufficient to promote adipogenesis39.
2.1.2 miRNA and insulin sensitivity—To identify miRNAs associated with insulin
sensitivity, He et al52 examined the miRNA expression profile by miRNA microarray
analysis of skeletal muscles from healthy and Goto-Kakizaki rats, a model of type 2
diabetes. miR-29 family members are upregulated in diabetic animals compared to control
animals. Northern blot analysis further revealed their upregulation in all three insulin-
responsive tissues including adipose tissue, muscle and liver of diabetic rats. Adenovirus-
mediated overexpression of miR-29 in 3T3-L1 largely repressed insulin-stimulated glucose
uptake, presumably through inhibiting Akt activation. High levels of miR-29 led to insulin
resistance mimicking the insulin resistance in cells incubated with high glucose and high
insulin. Interestingly, the miR-29 level was upregulated in the presence of high glucose
(hyperglycemia) and high insulin (hyperinsulinemia) in 3T3-L1 adipocytes. Two candidate
genes Insig1 (insulin-induced gene 1) and Cav2 (caveolin 2) were validated as targets of
miR-29 but their participation in insulin signaling pathway is not clear. Further studies are
needed to test whether higher level of miR-29 in insulin-responsive tissues result in lower
levels of target proteins.
With the observation that individual miRNAs moderately repress many targets, it is
tempting to hypothesize that a miRNA family or a miRNA cluster targeting multiple
components of the same signaling pathway may be more effective and functionally
important than a single miRNA. Xu and Wong performed a computational screen to identify
mouse signaling pathways targeted by miRNA clusters53. Most strikingly, one miRNA
cluster, mmu-mir-183-96-182 targets Irs1, Rasa1, and Grb2, all of which are located in the
insulin signaling pathway. These predictions were further supported experimentally by
luciferase report assays. This supports the notion that different members of one miRNA
cluster target different components along a signaling pathway and can coordinately control
the signal transduction process.
Studies in cancer cells also suggested insulin receptor substrate (IRS)-1 can be repressed at
the translation level by miR-145 and miR-12654, 55. Since IRS is an important component of
the insulin signaling pathway, it merits further investigation whether these interactions are
physiologically relevant and play a role in the pathogenesis of insulin resistance.
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2.1.3 miRNAs in different fat depots—Adipose tissue consists of white adipose tissue
(WAT) and brown adipose tissue (BAT). While WAT stores excess energy, BAT is very
active in energy expenditure and has an anti-obesity function56, 57. This property relies on
the expression of a BAT specific protein, UCP-1, which is a proton transporter located in the
inner mitochondrial membrane and allows dissipation of the proton electrochemical gradient
in the form of heat instead of ATP58.
While BAT persists through life in rodent, it has traditionally been considered insignificant
in adult human. In human fetuses and newborns, BAT is found in axillary, cervical,
perirenal, and periadrenal regions, but decreases shortly after birth56. However, using
morphological studies and positron-emission tomography scanning studies, three
independent groups have recently provided conclusive evidence for the existence of active
BAT in adults59–61. Importantly, the presence of BAT negatively correlates with both BMI
and percentage of body fat, whereas it positively correlates with resting metabolic rate,
implicating a role of BAT in preventing obesity in adult human.
White adipose tissue can be further subdivided into subcutaneous fat and visceral fat, which
is most closely related to insulin resistance56. Global miRNA expression comparison
between subcutaneous and omental fat, a type of visceral fat, from 15 human individuals
suggested little differences in these two fat depots overall62; this supports the notion that
subcutaneous and visceral fat are indeed two locations of a developmentally homogeneous
adipose organ.
Recently, exciting research suggested that white and brown adipocytes originate from
different precursors with brown preadipocytes being more closely related to skeletal muscle
cells than to white preadipocytes57. Investigation of miRNAs in brown fat has just begun.
miR-455, which is low in white pre- and mature adipocyte, was enhanced during brown
adipocyte differentiation, similarly to the expression pattern of the brown adipocyte
differentiation marker UCP-1 63; thus it may play a role during brown adipocyte
differentiation or contribute to the mature brown adipocyte function. Three classical
“myogenic” miRNAs, miR-1, miR-133a and miR-206 were absent from white adipocytes
but were specifically expressed both in brown pre- and mature adipocytes63. More
comprehensive high-throughput expression profiling studies should identify more miRNAs
specifically enriched in white fat, brown fat and muscle. Brown fat enriched miRNAs may
be related to energy expenditure and/or thermogenesis. In vitro and in vivo manipulation of
these brown fat enriched miRNAs, independently or together with transcription factors, may
help confer the brown adipocyte properties to white adipocyte or muscle cells, which may be
used clinically to treat obesity.
2.1.4 miRNA in obese adipose tissue—Adipose tissue undergoes a dramatic
expansion in obesity, which eventually results in adipose tissue dysfunction. As adipose
tissue expands, macrophage infiltration in adipose tissue occurs64. Chronic inflammation
and hypoxia are two principal features of obese adipose tissue in animals and humans64, 65.
Inflammatory cytokines including TNF-α are largely responsible for suppressing many
adipocyte-specific genes including PPARγ and adiponectin and reactivating expression of
many cell cycle genes, resulting in insulin resistance in obese adipose tissue66.
To compare miRNA expression levels in normal and obese states at a genome-wide scale,
Xie et al33 profiled the expression of more than 370 miRNAs in enriched epididymal
adipocytes from leptin deficient ob/ob and diet-induced obese (DIO) mice using miRNA
microarrays. A total of 71 miRNAs were expressed at significantly different levels in
adipocytes from wild type and ob/ob mice of the same gender and age whereas 35 miRNAs
were differentially expressed between control and DIO mice. Table 2 lists miRNAs either
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up- or down-regulated significantly regardless of the obesity model. There was a global
positive correlation of miRNA regulation in these two different models of obesity33,
suggesting that the changes in the adipocyte miRNA expression profile of ob/ob mice cannot
result from leptin deficiency alone, but likely associated with obesity in general.
Most importantly, miRNAs that were induced during adipogenesis were decreased in
adipocytes from both types of obese mice and vice versa33. For example, miR-422b,
miR-103, miR-30c were induced during adipogenesis but were downregulated in obese
adipocytes. Conversely, miR-221 and miR-222 were decreased during adipogenesis but
were upregulated in obese adipocytes. These changes are likely associated with the chronic
inflammatory environment and elevated TNF-α levels in obese adipose tissue, since they
were mimicked by TNF-α treatment of differentiated 3T3-L1 adipocytes33. The remarkable
inverse regulatory pattern for many miRNAs during adipogenesis and obesity has important
implications for understanding adipose tissue dysfunction in obese mice and humans and the
link between chronic inflammation and obesity with insulin resistance.
Independently, Lin et al39 observed the moderate increase of miR-27, a regulator of
adipogenesis discussed in the previous section, in epididymal fat tissue of ob/ob mice. They
found that miR-27 expression could be regulated by hypoxia, an important extracellular
stress associated with obesity. Whether miR-27 is regulated by inflammatory cytokines is
still an open question.
In human, significantly lower expression of miR-17-5p, miR-132 and miR-134 was found in
omental fat of overweight and obese individuals with newly diagnosed type 2 diabetes
compared to those with normal glucose tolerance, whereas the opposite pattern was found
for miR-181a62. Expression of miR-17-5p and miR-132 was negatively associated with
visceral fat area62. Most strikingly, lower expression of omental miR-132 was correlated
with higher macrophage infiltration whereas higher expression of miR-181a was correlated
with lower circulating adiponectin62. One possible caveat is that the unfractionated adipose
tissues profiled in their study contain many different cell types; thus the difference of certain
miRNAs may represent a decrease in the fraction of mature adipocytes in visceral adipose
tissue in type 2 diabetes patients, possibly as a result of infiltrating macrophages. Further
studies are necessary to dissect causal from correlative relationships and the association
needs to be confirmed in larger cohorts.
2.2 Liver
miR-122, a predominant miRNA in the liver, is involved in the regulation of several
cholesterol biosynthesis pathway genes67. In vivo inhibition of miRNA-122, in normal and a
diet induced obesity mouse model, resulted in a significant decrease in plasma cholesterol
levels and improvement in liver steatosis67, 68. In addition, the miR-30 family was recently
shown to be required for vertebrate hepatobiliary development, as knockdown of miR-30a in
zebrafish larva resulted in defective biliary morphogenesis69. Interestingly, hepatic function
was preserved up to 100 days old when Dicer1 was knocked out at birth in the differentiated
liver70. This was rather surprising considering the striking effect on cholesterol metabolism
when just miR-122 was knocked down. The authors suspected that additional miRNAs
contributed to the regulation of metabolic pathways and that global loss of all miRNAs
masks the phenotypes uncovered by the unbalanced inhibition of a single component of
miRNA-mediated regulation70.
Recently, Li et al71 analyzed the expression of miRNAs in livers of ob/ob mice,
streptozotocin (STZ)-induced type 1 diabetic mice and normal C57BL/6 mice by miRNA
microarray. Compared to normal C57BL/6 mice, ob/ob mice showed up-regulation of 8
miRNAs (miR-34a, miR-31, miR-103, miR-107, miR-194, miR-335-5p, miR-221, and
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miR-200a) and down-regulation of 4 miRNAs (miR-29c, miR-451, miR-21 and miR-122) in
fatty livers. Up-regulation of miR-34a and down-regulation of miR-122 was found in livers
of STZ-induced diabetic mice.
2.3 Pancreas
The role of miRNAs in insulin production (miR-30d), insulin secretion (miR-375, miR-9
and miR-96) and pancreatic islet development (miR-375 and miR-124a) have been reported
and extensively reviewed previously72–75. More recently, Poy et al76 reported that mice
lacking miR-375 are hyperglycemic, and exhibit increased total pancreatic alpha-cell
numbers, decreased beta-cell mass, higher fasting and fed plasma glucagon levels, and
increased gluconeogenesis and hepatic glucose output. More interestingly, increased
expression of miR-375 is observed in pancreatic islets of leptin-deficient ob/ob mice, which
also have increased beta-cell mass76. Genetic deletion of miR-375 from ob/ob mice
profoundly diminished the proliferative capacity of the endocrine pancreas and resulted in a
severe diabetic state76.
Another study by Lovis et al77 investigated the contribution of miRNAs to fatty acid
induced pancreatic beta-cell dysfunction. Prolonged exposure of the beta-cell line MIN6B1
and pancreatic islets to palmitate caused a time- and dose-dependent increase of miR-34a
and miR-146. Elevated levels of these miRNAs were also observed in islets of diabetic db/
db mice77. Blocking miR-34a or miR-146 activity partially protects palmitate-treated cells
from apoptosis77. Therefore, at least part of the detrimental effects of palmitate on beta-cells
is caused by alterations in the level of specific miRNAs.
3. Challenges and perspectives
3.1 Functional validation in animal models
As discussed so far, most gain-of-function or loss-of-function studies on miRNA have been
carried out in cell lines or primary cell cultures. The efficiency of knocking down miRNAs
in cell culture is still not optimized; thus, specific miRNA or miRNA cluster knockout mice,
especially conditional knockout mice, are the most powerful loss-of-function approach to
assess their role in development and obesity. Fortunately, the Sanger Institute in Cambridge
has started an initiative to create a library of knockouts of each of the 500 miRNAs
identified in the mouse genome78. The resource will eventually be available to all
researchers. Meanwhile, researchers may find some clues about miRNA function from
current knockout mice models for protein-coding genes because it is estimated that
expression of a miRNA may have been disrupted along with another gene in about 200
knockout cases79. However, it is challenging to knockout all miRNA family members that
are regarded to be functionally redundant if these family members are not on the same
chromosome. For example, miR-103/107 family members, miR-103-1, miR-103-2 and
miR-107, reside on three different chromosomes.
3.2 Combinatorial effect of miRNAs
Beside the fact that each mammalian miRNA regulates a large number of target genes,
several different miRNAs can act additively or synergistically at multiple target sites of a
single mRNA80. The potential interaction networks connecting miRNAs and mRNAs are
enormous and can be further expanded by feedback or feed-forward loops81. The effect of
single miRNA may be small and difficult to detect; nonetheless each probably makes an
important contribution to the robustness of the development of metabolic tissues and
pathogenesis of obesity and associated disorders. Ideally, one should manipulate multiple
candidate miRNAs in different combinations rather than changing one miRNA at a time for
functional characterization. However, this is labor intensive and technically challenging.
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3.3 Therapeutic strategies targeting miRNAs
With experimental evidence beginning to provide functional roles of miRNA in
development and metabolism, the need has become apparent to test miRNAs as viable
therapeutic targets. Some lessons learned from existing antisense technology and gene
therapy approaches can be adapted to manipulate miRNA levels in vivo.
Enhancement of miRNA activity can be accomplished by transfecting synthetic miRNA
mimetics or by using plasmids to transcribe miRNAs from endogenous or viral promoters.
Repression of miRNA activity can be performed with antisense oligonucleotides with
modifications to increase stability and binding specificity. Three major types of
modifications includes 2’-O-methyl (2’-O-Me), 2’-O-methoxyethyl (2’-O-MOE)
oligonucleotides and locked nucleic acids (LNAs)82. Initial studies exploiting these
modified antisense oligonucleotides to repress miRNA expression have shown promising
results in animals and non-human primates.
Of relevance to metabolism, Esau et al68 antagonized miR-122, a liver specific miRNA,
with 2’-O-MOE oligonucleotides in normal and diet-induced obese mice. When injected
intraperitoneally, miR-122 inhibition resulted in reduced plasma cholesterol levels in both
normal and diet-induced obese mice. Strikingly, miR-122 inhibition in a diet-induced
obesity mouse model significantly improved liver steatosis. Independently, Krutzfeldt et al67
used cholesterol-conjugated 2’-O-Me oligonucleotides (also known as antagomirs) to silence
miRNAs. Intravenous administration of antagomirs against miR-122 reduced plasma
cholesterol level significantly. The silencing of endogenous miRNAs by antagomirs seems
to be specific, efficient, and long-lasting. Most recently, Elmen et al83 used unconjugated
LNAs to antagonize miR-122 in non-human primates. Acute administration by intravenous
injections in African green monkeys resulted in uptake of LNAs in the cytoplasm of primate
hepatocytes and dose-dependent lowering of plasma cholesterol. Silencing of miR-122 was
efficient, long-lasting, and reversible without any evidence for LNA-associated toxicities or
histopathological changes. Additional examples of the use of antisense oligonucleotides
targeting miRNAs have been tabulated in a previous review article82. An alternative
approach of silencing miRNAs is the use of miRNA sponges, which contain multiple
tandem binding sites for targeted miRNAs, thereby acting as decoys to titrate miRNAs away
from their natural targets84. When miRNA sponges are expressed in a plasmid, the effect
can be long lasting. Two recent studies have utilized this strategy to inhibit miR-223 and
miR-31 in vivo85, 86. One can potentially inhibit multiple miRNAs with a single plasmid by
tandem decoy sequences against different miRNAs of interest.
In the future, and with better understanding of the upstream factors controlling miRNA
expression, we may be able to therapeutically increase or decrease expression of specific
miRNA(s) in disease tissue and thus ameliorate certain disease symptoms.
3.4 Delivery of therapeutic agents
Currently, there is an intense effort to identify agents capable of targeted delivery of nucleic
acids to specific tissues and cells87–92. One approach is conjugating a lipophilic moiety or
receptor ligand, such as cholesterol in the case of antagomirs, to the oligonucleotide.
Alternatively, oligonucleotides can be packed into liposomes, polymers, or nanoparticles
that facilitate endocytosis. Recently, combinatorial chemistry has yielded a novel class of
lipidoids that may allow for the development of new classes of delivery reagents93.
One challenge is the delivery method to transfer the miRNAs or its inhibitors into the
desired tissue. So far, much of the success has been obtained in liver. Some metabolic
tissues may be easier accessed and targeted than others in this regard. Circumventing this
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technical difficulty may involve development of different chemical modifications and
conjugates designed to specifically interact with cell-specific membrane proteins.
4. Conclusion
Emerging evidence from both gain- and loss-of-function studies suggests that miRNAs play
an important role in metabolic tissue development and function. Expression profiling studies
have revealed that some miRNAs are dysregulated in metabolic tissues under the obese
state, and possibly involved in the pathogenesis of various metabolic disorders. Further
functional characterization of metabolically important miRNAs in vitro and in vivo and
better understanding of their mechanism of action may allow for identification of novel
therapeutic targets and strategies. The safe, effective and targeted delivery of RNA
therapeutics remains an important challenge for clinical development.
5. Expert opinion
The complexity of post-transcriptional regulation by miRNA is still far from understood.
Further characterization of metabolically important miRNAs in vivo is likely to shed more
light on their functions. Large scale proteomics will help identify targets of a specific
miRNA since the effect of miRNAs is often more pronounced at the protein level than at the
mRNA level. Improved computational algorithms predicting miRNA targets will aid in this
effort as well. The potential interaction networks connecting miRNAs and mRNAs are
enormous and complex, thus a system biology approach is necessary to understand the entire
RNA regulatory network.
High-throughput miRNA profiling studies have and will continue to reveal miRNA
dysregulation in metabolic tissues. However, it is hard to dissect whether change of certain
miRNA cause metabolic tissue dysfunction or miRNA is dysregulated as a consequence of
metabolic tissue dysfunction. Establishment of the causal relationship will enable better
selection of therapeutically potential targets.
Recently, many genome-wide association studies have identified susceptibility loci and gene
polymorphisms for obesity and type 2 diabetes94–98. Some of these polymorphisms may
create or destroy a putative miRNA target site responsible for the phenotypic variation. As
an example, Villuendas et al99 showed that the ACAA-insertion/deletion polymorphism at
the 3’UTR of the insulin-like growth factor II receptor (IGF2R) was associated with type 2
diabetes and surrogate markers of insulin resistance. Most strikingly, using luciferase
reporter assays, Lv et al100 showed that hsa-miR-657 acts directly at the 3′UTR of the
IGF2R and the repression was greater when ACAA was deleted. This finding raise the
possibility that the ACAA-insertion/deletion polymorphism may result in the change of
IGF2R expression levels at least in part by hsa-miR-657-mediated regulation, contributing
to the pathogenesis of type 2 diabetes.
Since miRNAs have been shown to be differentially expressed in healthy and disease
states101, it is tempting to use miRNA as biomarkers for diagnosis. Excitingly, Chen et al102
demonstrated that miRNAs were present in serum and plasma of humans and other animals.
miRNA levels in serum are stable, reproducible and consistent among individuals of the
same species. Using high-throughput sequencing, they identified specific expression patterns
of serum miRNAs for lung cancer, colorectal cancer, and diabetes102. In addition, 17
miRNAs were exclusively detected in serum compared to blood cells from diabetic
patients102. Although the source of these miRNAs is not yet clear, a serum miRNA
fingerprint could complement the current biomarker, C-reactive protein (CRP) for the
diagnosis of diabetes. It would be interesting to find out when these serum miRNA
expression change respect to disease progression.
Xie et al. Page 10
Expert Opin Ther Targets. Author manuscript; available in PMC 2011 October 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In conclusion, miRNAs are promising therapeutic targets for management of obesity and
related metabolic disorders. With this great promise, many biotech firms are springing up to
develop miRNA-based products that can diagnose, treat, or predict the course of disease103.
However, to realize the full potential of miRNA-based therapeutics, more efficient and
specific silencing of miRNA and targeted delivery are needed.
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Figure 1.
miRNA biogenesis and mechanisms of action.
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Table 1
Mammalian miRNAs regulating adipogenesis and insulin sensitivity.
miRNA Function Model system Targets References
miR-143 Pro-adipogenic Primary human preadipocytes, 3T3-L1 ERK5/MAPK7(?) 33, 37
miR-103 Pro-adipogenic 3T3-L1 33
miR-200 Pro-adipogenic ST2 47
miR-17–92 cluster Pro-adipogenic 3T3-L1 Rb2/p130 38
Let-7 Anti-adipogenic 3T3-L1 Hmga2 40
miR-27 Anti-adipogenic 3T3-L1, OP9 39
miR-29 Inhibitor of glucose uptake 3T3-L1 Insig1(?), Cav2(?) 52
3T3-L1, mouse preadipocyte cell line; ST2 and OP9, mouse bone marrow stromal cells
?
Validated targets but their participation in adipogeneis or insulin signaling pathway is not clear
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Table 2
Principal miRNAs differentially regulated in enriched mouse epididymal adipocytes from both types of obese
mice (ob/ob and DIO) compared to wild type mice. Analysis is performed on the miRNA profiling data
described by Xie et al 33.
Up-regulated in obese mice Down-regulated in obese mice
miR-16
miR-24
miR-221
miR-222
miR-223
miR-146b
miR-23b
miR-27a
miR-27b
miR-342-3p
let-7d(*)
miR-103
miR-107
miR-145
miR-320
miR-30a*
Mature miRNAs are referred to by their names in miRBase version 10.1
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